Utilization of a murine model to optimize volume and dwell time of intraperitoneal cisplatin

Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma

“…Investigations in a rat model revealed that nephrotoxicity after injection of 1 to 5 mg/kg or infusion of 5 to 25 mg/kg was ameliorated after intermittent bolus injection and continuous infusion (over 2 and 3 hours). 13,28 In our project the delivered dose of 100 mg/m 2 cisplatin corresponded to 3 mg/kg. Therefore nephrotoxicity of the procedure was expected to remain low.…”

“…Local application of cisplatin (Platinol, Bristol-Myers Squibb) has already been performed intraperitoneally in ovarian carcinoma and intrapleurally in malignant mesothelioma in animal models and in patients at a dose between 80 and 150 mg/m 2 . 5,[7][8][9][13][14][15][16] It was demonstrated that cisplatin given at high doses is active in mesothelioma, but the response duration was short, possibly because of a lack of effective maintenance of therapy. 5,7,13 The aim of this study was to investigate whether local topical intrapleural application of cisplatin with the aid of surgical autologous fibrin sealant (Vivostat, Vivolution) has a prolonged local pharmacologic tissue level in comparison with local administration without sealant while reducing systemic drug exposure in an immune-competent rat model.…”

Dissemination of intraperitoneal ovarian cancer: Discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model

“…The available systems range from in vitro model such as ovarian cancer cell lines to animal models. These models include human xenografts [28], an immunogenic chemically induced rat ovarian tumor [29], a germ cell tumor model [30] and models of non-ovarian tumors injected intraperitoneal [31]. Although each of these models has its applications in medical research, they are not ideal for the study of immunologic response to therapy, and to understand the biological features and behavior of the most frequent type of ovarian cancer cells.…”

Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat

“…These include (1) human ovarian tumors xenografted into nude mice, 3 (2) chemically induced rat ovarian tumors, 4 (3) transplantable murine germ cell tumors, 5 and (4) 6 Although the human tumor-nude mouse xenograft model has shown utility for drug screening, the nude mouse lacks a competent immune system and hence is inappropriate for studies in which an intact immune system would be necessary. Moreover, the growth of human tumors in nude mice may obviate important physiologic interactions such as growth factor dependency or immune cell responses because of the xenogeneic-immunodeficient nature of the model.…”

“…Currently available systems range from in vitro models such as ovarian cancer cell lines to several animal models. These models include (1) human ovarian cancer xenografts, 3 (2) an immunogenic chemically induced rat ovarian tumor, 4 (3) a germ cell tumor model, 5 and (4) models of nonovarian tumors injected intraperitoneally. 6 Although each of these models has applications in medical research, they are clearly not ideal for the study of the immunologic response to therapy and the biologic features of the most frequent form of ovarian cancer.…”